Mac-Chem Products (India) Pvt.Ltd DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

With Fermion, start the journey of your innovative API.

Virtual Booth

Contact Supplier

Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 2 News #PharmaBuzz

media
Interview #SpeakPharma
Vlog #PharmaReel
Data Compilation #PharmaFlow
2 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

97 All APIs, 14 USDMF, 13 CEP/COS, 35 EU WC, 7 KDMF, 91 Listed APIs

97 All APIs
14 USDMF
13 CEP/COS
35 EU WC
7 KDMF
91 Listed APIs

SERVICES

API Manufacturing

pharmaServices
API Manufacturing

INSPECTIONS & REGISTRATIONS

1 FDA, 1 EDQM, 1 WHO-GMP

inspections
1 FDA
1 EDQM
1 WHO-GMP

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Established in 2010, Mac-Chem is a NMM Group company. Mac-Chem is focused on oncology and other niche specialty APIs. It supplies quality APIs to the top 15 oncology players in India. It is also the sole manufacturer of some of the molecules in the oncology segment and general segment. The company’s investments are mostly geared toward exports, especially to regulated markets. Mac-Chem has a cGMP-compliant manufacturing facility near Mumbai in India. The company’s facility is USFDA, EDQM, COFEPRIS, ANVISA, MFDS-Korea, WHO-GMP-approved and ISO-certified. Mac-Chem enjoys a global reach, serving more than 40 countries.

CPhI South East AsiaCPhI South East Asia

Not Confirmed

Not Confirmed

16-18 July, 2025

MITEC, Kuala Lumpur, Malaysia
Specialty & Agro Chemi...Specialty & Agro Chemical

Not Confirmed

Not Confirmed

29 June-01 July, 2025

Savannah, Georgia
Discovery EuropeDiscovery Europe

Not Confirmed

Not Confirmed

01-02 July, 2025

Basel, Switzerland

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

India

Address

304, Town Centre, 3rd Floor, Andheri (East), Mumbai 400059

Telephone

91 22 4093 9000

enquiries@pharmacompass.com

Website

https://www.macchemgroup.com/

https://in.linkedin.com/company/mac-chem-product-india-pvt-ltd

YouTube

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]

Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1235

VLOG #PharmaReel

[Sponsored by another company]

Providing RSMs & API to Global Pharma Companies

This PharmaReel showcases Allsino Pharmaceutical, a company that provides GMP-certified RSMs and APIs to global pharma companies, specializing in peptides, oligonucleotides, and small molecule CDMO services. Allsino has a presence in the US, EU, China and Japan.

Impressions: 1215

DATA COMPILATION #PharmaFlow

[Sponsored by another company]

J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

The pharmaceutical industry has witnessed a wave of mergers, acquisitions, and strategic partnerships so far in the first half (H1) of 2025, with deal values exceeding US$ 170 billion.PharmaCompass’ data shows oncology alone accounted for nearly US$ 47 billion in deal value, followed by US$ 18 billion each in immunology and psychiatry, US$ 17 billion in nutrition/weight loss and US$ 7 billion in neurology.Pharma majors such as Johnson & Johnson and Bristol Myers Squibb led with two deals worth over US$ 10 billion each. Sanofi executed a series of deals in the immunology and neuro-inflammation space. And Eli Lilly stood out for its aggressive dealmaking, which spanned oncology, pain, RNA therapies, and AI-driven oligonucleotides. In all, it signed seven deals worth over US$ 1 billion each. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available)H1 records several mega deals as J&J buys Intra-Cellular, BMS ties up with BioNTech, Sanofi acquires BlueprintJohnson & Johnson dominated headlines with its US$ 14.6 billion acquisition of Intra-Cellular Therapies in January 2025. This marks the largest biopharma deal since Novo Nordisk’s US$ 16.5 billion acquisition of Catalent in February 2024. This acquisition positions J&J as a formidable player in the neuroscience space. Bristol Myers Squibb entered into a US$ 11.1 billion partnership with BioNTech. The deal structure — US$ 3.5 billion in unconditional payments and up to US$ 7.6 billion in milestone payments — demonstrates BMS’ confidence in BNT327, a next-generation bispecific antibody in phase 3 trials for treating extensive stage small cell lung cancer and non-small cell lung cancer.Sanofi acquired Blueprint Medicines for US$ 9.5 billion in order to enhance its rare disease portfolio. The French drugmaker is also creating a comprehensive immunology portfolio. The company signed a US$ 1.9 billion deal for Dren Bio’s DR-0201 bispecific antibody for autoimmune diseases. Sanofi also acquired Vigil Neuroscience for US$ 470 million for its phase 2-ready Alzheimer’s disease candidate. Additionally, the drugmaker secured a US$ 1.84 billion global license agreement with Earendil Labs for two next-generation bispecific antibodies.Pfizer’s US$ 6.05 billion partnership with 3SBio provides it global licensing rights (excluding China) for SSGJ-707, a bispecific antibody currently undergoing multiple clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Obesity gold rush sees Roche, AbbVie, Sciwind ink deals; Novo pledges over US$ 5 bn across three dealsThe obesity therapeutics market has triggered intense competition among pharmaceutical giants. Roche’s US$ 5.3 billion partnership with Zealand Pharma is focused on petrelintide, an amylin analog designed to preserve lean mass better than existing GLP-1-based treatments. The collaboration combines petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388, creating a differentiated obesity treatment.Market leader Novo Nordisk has promised over US$ 5 billion across three major obesity deals in 2025. The US$ 2.2 billion Septerna collaboration targets oral small molecule medicines for obesity and cardiometabolic diseases.Novo signed a separate US$ 2 billion agreement with China’s United Biotechnology for UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors in phase 2 clinical development for obesity, type 2 diabetes, and other diseases. The company’s third major deal, a US$ 1 billion partnership with Lexicon Pharmaceuticals, provides it access to LX9851, a molecule in preclinical development for obesity and associated metabolic disorders.Sciwind Biosciences secured a US$ 2.5 billion global licensing and collaboration agreement with Verdiva Bio Limited for the global development and commercialization of a portfolio of metabolic diseases therapies. AbbVie entered the amylin arena through its US$ 2.2 billion Gubra partnership for GUB014295, a candidate in phase 1 trials for treating obesity. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Molecular glue degraders draw investments; Lilly signs seven deals over US$ 1 billion eachMolecular glue degraders have emerged as a transformative therapeutic modality, attracting significant investment across multiple partnerships. AbbVie’s US$ 1.64 billion collaboration with Neomorph leverages the biotech’s leading molecular glue discovery platform for oncology and immunology applications.Genentech’s potential US$ 2.1 billion partnership with Orionis Biosciences focuses on small-molecule monovalent glue medicines for novel and challenging oncology targets. This is the second partnership between the two companies, following their initial 2023 collaboration.Eli Lilly has collaborated with Magnet Biomedicine, utilizing Magnet’s TrueGlue discovery platform for oncology applications. The deal could be worth up to US$ 1.3 billion.Eli Lilly has emerged as one of 2025’s most active dealmakers, with approximately seven deals exceeding US$ 1 billion each. The company’s US$ 2.5 billion Scorpion Therapeutics acquisition provides access to STX-478, an experimental oral therapy in early-stage trials for breast cancer and advanced solid tumors, potentially addressing 30 to 40 percent of hormone-positive breast cancer patients.On June 17, Lilly announced the acquisition of gene-editing startup Verve Therapeutics for US$ 1.3 billion. Lilly’s US$ 1 billion SiteOne acquisition announced in May brings STC-004, a phase 2-ready non-opioid chronic pain treatment to its pipeline. Other partnerships announced by Lilly include a US$ 1.4 billion capsid licensing deal with Sangamo for central nervous system disease genomic medicines and a US$ 1.3 billion collaboration with South Korean company Rznomics for RNA-based hearing loss treatments. Lilly has also strengthened its oligonucleotide pipeline through a potential US$ 1 billion collaboration with Creyon Bio for AI-designed oligonucleotide therapies targeting RNA. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Merck KGaA acquires SpringWorks for US$ 3.9 bn; Novartis buys out Anthos for US$ 3.1 bnAstraZeneca signed a US$ 5.3 billion AI-led research agreement with China’s CSPC Pharmaceuticals Group to advance the discovery of novel oral candidates for immunological diseases. Merck KGaA acquired SpringWorks for US$ 3.9 billion in April, which gave it access to two FDA-approved therapies — Ogsiveo (nirogacestat), the first and only approved therapy for adult patients with progressing desmoid tumors requiring systemic treatment, and Gomekli (mirdametinib), the first and only FDA-approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.Novartis’ US$ 3.1 billion Anthos Therapeutics acquisition centered around abelacimab, a potential first-in-class monoclonal antibody currently in three phase 3 studies for stroke and systemic embolism prevention in atrial fibrillation patients.GSK’s US$ 2 billion acquisition of Boston Pharmaceuticals’ efimosfermin targets steatotic liver disease (fatty liver disease). The medicine is also in clinical development for MASH treatment. GSK’s second major deal involved the US$ 1.15 billion acquisition of US biotech IDRx, strengthening its gastrointestinal cancer portfolio.The pharma industry also drew some private equity interest as Bain Capital acquired Japan’s Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group for US$ 3.3 billion. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Our viewDespite an uncertain geopolitical environment, the year has seen a surge in M&As and dealmaking in the first half of 2025. However, a sizable chunk of the acquisitions were bolt-on transactions, indicating that companies are not ready to take on risks, and are buying out smaller players who strategically fit into their operations. Going forward, there are indications that M&A activity will stay strong throughout 2025.

Impressions: 2783

NEWS #PharmaBuzz

Mac-Chem Products’ Boisar facility successfully renews EU-GMP certification

18 Apr 2024

// PHARMABIZ

Mac-Chem Products Fails EDQM Inspection

16 Nov 2022

// EDQM

ALL APIs

Click the button for full data set

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Services

Upload your portfolio for free, ask us

API Manufacturing

Click here to discover the service providers for API Manufacturing

Scale Up

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GMP Manufacturing

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Cytotoxic Compound

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Injectable / Sterile APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

High Potency APIs (HPAPIs)

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Upload your audits for free, ask us

FDA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

WHO-GMP

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact Mac-Chem Products (India) Pvt.Ltd and get a quotation

Mac-Chem Products (India) Pvt.Ltd is a supplier offers 93 products (APIs, Excipients or Intermediates).

Find a price of Bicalutamide bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Cytarabine bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Irinotecan Hydrochloride bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Ropivacaine Hydrochloride bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Succinylcholine Chloride bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Capecitabine bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Carboplatin bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Dacarbazine bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Letrozole bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Neostigmine Methylsulfate bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Pemetrexed Disodium bulk with CEP, WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Anastrozole bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Docetaxel bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Gefitinib bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Oxaliplatin bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Paclitaxel bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Abiraterone Acetate bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Acyclovir bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Bendamustine Hydrochloride bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Chloramphenicol Sodium Succinate bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Colistimethate Sodium bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Erlotinib Hydrochloride bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Esomeprazole Sodium bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Gemcitabine bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Hydrocortisone Sodium Succinate bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Methotrexate bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Methylprednisolone Sodium Succinate bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Omeprazole Sodium bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Pantoprazole Sodium bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Polymyxin B Sulfate bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Succinylcholine Chloride bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Tenoxicam bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Zoledronic Acid bulk with WC offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Cisplatin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Exemestane bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Afatinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Anidulafungin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Aprepitant bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Axitinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Azacitidine bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Bortezomib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Cabazitaxel bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Carfilzomib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Choline Chloride bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Cladribine bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Dabigatran Etexilate Mesylate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Daptomycin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Dasatinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Dexmedetomidine Hydrochloride bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Enzalutamide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Epinephrine Bitartrate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Eribulin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Etoposide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Everolimus bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Fludarabine Phosphate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Fosaprepitant bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Fosfomycin Sodium bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Gefitinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Glimepiride bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Glutathione bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Hydrocortisone bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Hydrocortisone Acetate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Ibrutinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Idelalisib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Imatinib Mesylate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Ketoprofen bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Lapatinib Ditosylate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Lenalidomide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Lenvatinib Mesylate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Methylprednisolone bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Methylprednisolone Hemisuccinate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Micafungin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Neostigmine Bromide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Nilotinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Nintedanib Esylate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Norepinephrine Bitartrate bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Olaparib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Palbociclib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Pazopanib Hydrochloride bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Pomalidomide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Rabeprazole Sodium bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Rocuronium Bromide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Sorafenib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Sugammadex Sodium bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Sunitinib bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Teicoplanin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Temozolomide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Tigecycline bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Topotecan Hydrochloride bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Trabectedin bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Vancomycin Hydrochloride bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Vecuronium Bromide bulk offered by Mac-Chem Products (India) Pvt.Ltd

Find a price of Voriconazole bulk offered by Mac-Chem Products (India) Pvt.Ltd

Company profile for Mac-Chem Products (India) Pvt.Ltd